ATTENTION, GLAXO (GSK): Human Genome's (HGSI) Cut-Off Date is July 16th, Will Provide Details to Interested Parties

June 15, 2012 7:12 AM EDT
Get Alerts HGSI Hot Sheet
Trade HGSI Now!
Join SI Premium – FREE
In an effort to get the message across, Human Genome Sciences, Inc. (Nasdaq: HGSI) today repeated an earlier announcement. Careful analysis reveals nothing different between the two:

From the release:

"Human Genome Sciences today announced that, in connection with its ongoing strategic alternative review process, it had previously set a bid date of July 16, 2012 for the submission of definitive proposals to acquire all outstanding common shares of HGS. In this regard, HGS yesterday sent a letter to GlaxoSmithKline (GSK) once again inviting GSK to participate in the ongoing process according to the same procedures previously established and to provide, by no later than July 16, 2012, GSK’s final bid terms, including a response to a draft agreement which will be provided to all interested bidders. The letter specifically noted that the HGS Board of Directors has previously rejected $13.00 per share as inadequate.

HGS is committed to completing its exploration of strategic alternatives in a manner that ensures that HGS stockholders have the benefit of a complete and fair process and welcomes GSK to fully participate in such process.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Mergers and Acquisitions

Add Your Comment